PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Technological Innovations Expand the Capabilities of Mass Spectrometers - The acceptance of mass spectrometric techniques in research institutions across Europe is being driven by their inherent advantages such as increased accuracy and higher throughput ratio
Technological Innovations Expand the Capabilities of Mass Spectrometers

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/09/18 - The acceptance of mass spectrometric techniques in research institutions across Europe is being driven by their inherent advantages such as increased accuracy and higher throughput ratio.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Mass spectrometry (MS) has found significant use in the pharmaceutical and biotechnology sectors, where primary applications include the characterisation of protein and other biologically active entities.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), Opportunities for the European Mass Spectrometry Markets in Basic Research Applications, finds that the market earned revenues of $562 million in 2007 and estimates this to reach $1078.8 million in 2014.

"In the field of environmental sciences, the analytical capabilities of MS platforms are extensively used in the identification of numerous toxins and pollutants," notes Frost & Sullivan Research Analyst Suraj Ramanathan. "The influence of this technology has reached areas such as forensic science. Further areas of interest include polymer analysis, environmental sciences, food safety and nutrition, drug abuse and rehabilitation, defence research and space research."

Furthermore, the discovery of disease biomarkers has helped expand the capabilities of this analysis platform. The Fourier Transform Mass Spectrometry (FTMS) segment is showing maximum growth, with a higher degree of technical innovation.

Many MS manufacturers have come out with customised research programs that suit end-user requirements. This has led to numerous research and marketing agreements between MS manufacturers and companies and research organisations over a wide spectrum.

However, one of the most important challenges facing the European mass spectrometry markets is the increase in strategic consolidations within the pharmaceutical industry, which is reducing buying power. Product pricing issues, changes in funding towards clinical research, funding from the private sector and reduced manpower for operating instruments are some of the other challenges confronting market participants.

"Compensating on logistical costs, many pharmaceutical companies have started outsourcing their R&D initiatives to countries such as India and China that are comparatively high on resources and manpower," notes Ramanathan. "This reduces the need for high-tech instruments within Europe."

With end users concerned about the shortage of skilled technicians to operate MS, manufacturers need to develop training programs to enable first-time users to familiarize themselves with the platform. Manufacturers could also regularly update end users on technological advancements in the field of study with respect to MS usage. This would aid them in applying MS in their research areas, strengthening customer relationship.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the opportunities for the European mass spectrometry markets in basic research applications, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

Opportunities for the European Mass Spectrometry Markets in Basic Research Applications is part of the Drug Discovery & Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: European Molecular Diagnostics Markets, European IVD Market and European Cancer Diagnostic Market, European Primary Care Diagnostics. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Opportunities for the European Mass Spectrometry Markets in Basic Research Applications
M229

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Technological Innovations Expand the Capabilities of Mass Spectrometers

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)